Clinical study of compound Anisodine combined with vitamin B12 in treating diabetic optic neuropathy patients with long-term use of metformin

Objective To investigate clinical results of compound anisodine combined with vitamin B12 for type 2 diabetes optic neuropathy patients with long-term use of metformin. Methods From January 2015 to December 2015, 186 cases of type 2 diabetes optic neuropathy with long-term use of metformin admitted to the outpatients in our hospital for the clinical study and were randomly divided into control group (93 cases) and observation group (93 cases), serum vitamin B12 levels were determined. On the basis of taking metformin for controlling blood glucose, the control group was treated with the compound anisodine 2ml subcutaneous injection beside the affected side arteriae temporalis superficialis and the observation group was treated with the mixture of the compound anisodine 2ml and vitamin B12 0.2ml subcutaneous injection beside the affected side arteriae temporalis superficialis. The both groups were once a day and the period of treatment were three courses (two weeks for one course). After three courses of treatment, visual acuity, field of vision and retinal nerve fiber layer thickness changes of two groups were compared and the security of the compound anisodine combined with vitamin B12 for diabetes optic neuropathy were observed. Results After treatment, total effective rate of the control group and observation group were 56% and 78.6% respectively, and the difference was statistically significant (P <0.05). During treatment, it showed no significant adverse reactions. Conclusions The clinical results of compound anisodine combined with vitamin B12 are more significant than the compound anisodine only for type 2 diabetes optic neuropathy patients with long-term use of metformin.